◎ Sugi Atlas

Atlas / Drug / Sovleplenib

Sovleplenib

drug
On this page

Also known as HMPL 523Hmpl-523HMPL523

Summary

Sovleplenib (CHEMBL5095034) is a phase-3 clinical-stage small molecule targeting SYK; indicated across 10 conditions including autoimmune thrombocytopenic purpura and neoplasm.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Small molecule
  • Targets: 1 (SYK)
  • Indications: 10 conditions
  • Clinical trials: 14
  • Chemistry: 482.6 Da · C24H30N6O3S

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL5095034
NameSovleplenib
TypeSmall molecule
Max phase3
FDA approvedno
PubChem CID166625231
Molecular formulaC24H30N6O3S
Molecular weight482.6
InChIKeyBRCHZKBUGSKTND-FQEVSTJZSA-N

SMILES: CS(=O)(=O)N1CCC(CC1)C2=CC=C(C=C2)C3=C(C4=NC=CN=C4C=N3)NC[C@@H]5CNCCO5

IUPAC name: 7-[4-(1-methylsulfonylpiperidin-4-yl)phenyl]-N-[[(2S)-morpholin-2-yl]methyl]pyrido[3,4-b]pyrazin-8-amine

Also known as: HMPL 523, Hmpl 523, Hmpl-523, HMPL-523, HMPL523, Sovleplenib, SOVLEPLENIB

Parent form; salt/anhydrous children: CHEMBL6068429

Patent coverage: 111 distinct patent families (377 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
SYKspleen associated tyrosine kinaseInhibition92%P43405

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): SYK.

Top Reactome pathways

47 total, by targets touching each:

PathwayTargetsGenes
Hemostasis1SYK
GPVI-mediated activation cascade1SYK
Cytokine Signaling in Immune system1SYK
Adaptive Immune System1SYK
Signal Transduction1SYK
Disease1SYK
Innate Immune System1SYK
Immune System1SYK
Fcgamma receptor (FCGR) dependent phagocytosis1SYK
FCGR activation1SYK
Regulation of actin dynamics for phagocytic cup formation1SYK
Role of phospholipids in phagocytosis1SYK
DAP12 interactions1SYK
DAP12 signaling1SYK
Fc epsilon receptor (FCERI) signaling1SYK
Role of LAT2/NTAL/LAB on calcium mobilization1SYK
FCERI mediated MAPK activation1SYK
FCERI mediated Ca+2 mobilization1SYK
Integrin signaling1SYK
Signaling by Interleukins1SYK
Interleukin-2 family signaling1SYK
Interleukin-3, Interleukin-5 and GM-CSF signaling1SYK
CLEC7A (Dectin-1) signaling1SYK
Dectin-2 family1SYK
C-type lectin receptors (CLRs)1SYK
Infectious disease1SYK
Platelet activation, signaling and aggregation1SYK
Platelet Aggregation (Plug Formation)1SYK
Interleukin-2 signaling1SYK
Regulation of signaling by CBL1SYK

Dominant GO biological processes

GO termTargets
angiogenesis1
cell activation1
lymph vessel development1
positive regulation of receptor internalization1
stimulatory C-type lectin receptor signaling pathway1
adaptive immune response1
macrophage activation involved in immune response1
neutrophil activation involved in immune response1
leukocyte activation involved in immune response1
serotonin secretion by platelet1
cell surface pattern recognition receptor signaling pathway1
negative regulation of inflammatory response to antigenic stimulus1
protein phosphorylation1
protein import into nucleus1
leukocyte cell-cell adhesion1

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
autoimmune thrombocytopenic purpura3MONDO:0008558EFO:0007160
neoplasm2MONDO:0005070EFO:0000616
autoimmune hemolytic anemia2MONDO:0020108EFO:1001264
rheumatoid arthritis1MONDO:0008383EFO:0000685
acute myeloid leukemia1MONDO:0018874EFO:0000222
non-Hodgkin lymphoma1MONDO:0018908EFO:0005952
lymphoma1MONDO:0005062EFO:0000574
autoimmune disease1MONDO:0007179EFO:0005809

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

PhaseTrials
PHASE112
PHASE31
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05029635PHASE3COMPLETEDPhase III Study on HMPL-523 for Treatment of ITP
NCT02105129PHASE1COMPLETEDA Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523
NCT02503033PHASE1UNKNOWNA Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
NCT02857998PHASE1COMPLETEDA Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
NCT03483948PHASE1TERMINATEDPhase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
NCT03779113PHASE1TERMINATEDAn Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
NCT03951623PHASE1COMPLETEDThe Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
NCT05571787PHASE1COMPLETEDHMPL-523 Food Effect and Proton Pump Inhibitor Study
NCT05720767PHASE1COMPLETEDHMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
NCT05781906PHASE1COMPLETEDHuman Mass Balance of [14C]HMPL-523 in Healthy Adult Male Chinese Subjects
NCT06291415PHASE1WITHDRAWNThe Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT07331194PHASE1COMPLETEDPharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans
NCT07348133PHASE1COMPLETEDStudy of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets
NCT05318820EARLY_PHASE1COMPLETEDA Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

54 molecules share ≥1 primary target. Top 54 by shared-target count:

MoleculeSourceStatusShared targets
CRIZOTINIBChEMBL + PubChemPhase 4 (approved)SYK
FOSTAMATINIBChEMBL + PubChemPhase 4 (approved)SYK
PAZOPANIBChEMBL + PubChemPhase 4 (approved)SYK
BOSUTINIBChEMBLPhase 4 (approved)SYK
CERITINIBChEMBLPhase 4 (approved)SYK
DASATINIBChEMBLPhase 4 (approved)SYK
ENTRECTINIBChEMBLPhase 4 (approved)SYK
ERLOTINIBChEMBLPhase 4 (approved)SYK
FEDRATINIBChEMBLPhase 4 (approved)SYK
FOSTAMATINIB DISODIUMChEMBLPhase 4 (approved)SYK
GILTERITINIBChEMBLPhase 4 (approved)SYK
IMATINIBChEMBLPhase 4 (approved)SYK
INFIGRATINIBChEMBLPhase 4 (approved)SYK
MIDOSTAURINChEMBLPhase 4 (approved)SYK
NERATINIBChEMBLPhase 4 (approved)SYK
CEDIRANIBChEMBLPhase 3SYK
ENTOSPLETINIBChEMBLPhase 3SYK
LESTAURTINIBChEMBLPhase 3SYK
QUERCETINChEMBLPhase 3SYK
ADAVOSERTIBChEMBLPhase 2SYK
APITOLISIBChEMBLPhase 2SYK
AT-9283ChEMBLPhase 2SYK
BERZOSERTIBChEMBLPhase 2SYK
BI-2536ChEMBLPhase 2SYK
CENISERTIBChEMBLPhase 2SYK
CERDULATINIBChEMBLPhase 2SYK
DANUSERTIBChEMBLPhase 2SYK
FISETINChEMBLPhase 2SYK
FORETINIBChEMBLPhase 2SYK
GENISTEINChEMBLPhase 2SYK
GLESATINIBChEMBLPhase 2SYK
GUSACITINIBChEMBLPhase 2SYK
ILORASERTIBChEMBLPhase 2SYK
LANRAPLENIBChEMBLPhase 2SYK
LUTEOLINChEMBLPhase 2SYK
MIVAVOTINIBChEMBLPhase 2SYK
PELITINIBChEMBLPhase 2SYK
R-112ChEMBLPhase 2SYK
R-343ChEMBLPhase 2SYK
R-406ChEMBLPhase 2SYK
RAF-265ChEMBLPhase 2SYK
REBASTINIBChEMBLPhase 2SYK
TOP-1288ChEMBLPhase 2SYK
TOZASERTIBChEMBLPhase 2SYK
UCN-01ChEMBLPhase 2SYK
AfatinibPubChemApprovedSYK
belumosudilPubChemApprovedSYK
BinimetinibPubChemApprovedSYK
dacomitinibPubChemApprovedSYK
GefitinibPubChemApprovedSYK
IdelalisibPubChemApprovedSYK
regorafenibPubChemApprovedSYK
SelumetinibPubChemApprovedSYK
TrametinibPubChemApprovedSYK

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot